Publication

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer

Shimelis, H., Mesman, R. L. S., Von Nicolai, C., Ehlen, A., Guidugli, L., Martin, C., Calleja, F. M. G. R., Meeks, H., Hallberg, E., Hinton, J., Lilyquist, J., Hu, C., Aalfs, C. M., Aittomaki, K., Andrulis, I., Anton-Culver, H., Arndt, V., Beckmann, M. W., Benitez, J., Bogdanova, N. V., Bojesen, S. E., Bolla, M. K., Borresen-Dale, A-L., Brauch, H., Brennan, P., Brenner, H., Broeks, A., Brouwers, B., Bruning, T., Burwinkel, B., Chang-Claude, J., Chenevix-Trench, G., Cheng, C-Y., Choi, J-Y., Collee, J. M., Cox, A., Cross, S. S., Czene, K., Darabi, H., Dennis, J., Dork, T., dos-Santos-Silva, I., Dunning, A. M., Fasching, P. A., Figueroa, J., Flyger, H., Garcia-Closas, M., Giles, G. G., Glendon, G., Oosterwijk, J. J. C., KConFab AOCS Investigators & NBCS Collaborators, 1-Jun-2017, In : Cancer Research. 77, 11, p. 2789-2799 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer

    Final publisher's version, 934 KB, PDF document

DOI

  • Hermela Shimelis
  • Romy L. S. Mesman
  • Catharina Von Nicolai
  • Asa Ehlen
  • Lucia Guidugli
  • Charlotte Martin
  • Fabienne M. G. R. Calleja
  • Huong Meeks
  • Emily Hallberg
  • Jamie Hinton
  • Jenna Lilyquist
  • Chunling Hu
  • Cora M. Aalfs
  • Kristiina Aittomaki
  • Irene Andrulis
  • Hoda Anton-Culver
  • Volker Arndt
  • Matthias W. Beckmann
  • Javier Benitez
  • Natalia V. Bogdanova
  • Stig E. Bojesen
  • Manjeet K. Bolla
  • Anne-Lise Borresen-Dale
  • Hiltrud Brauch
  • Paul Brennan
  • Hermann Brenner
  • Annegien Broeks
  • Barbara Brouwers
  • Thomas Bruning
  • Barbara Burwinkel
  • Jenny Chang-Claude
  • Georgia Chenevix-Trench
  • Ching-Yu Cheng
  • Ji-Yeob Choi
  • J. Margriet Collee
  • Angela Cox
  • Simon S. Cross
  • Kamila Czene
  • Hatef Darabi
  • Joe Dennis
  • Thilo Dork
  • Isabel dos-Santos-Silva
  • Alison M. Dunning
  • Peter A. Fasching
  • Jonine Figueroa
  • Henrik Flyger
  • Montserrat Garcia-Closas
  • Graham G. Giles
  • Gord Glendon
  • Jan J. C. Oosterwijk
  • KConFab AOCS Investigators
  • NBCS Collaborators

Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between 19 BRCA1 and 33 BRCA2 missense substitution variants and breast cancer risk were investigated through a breast cancer case-control study using genotyping data from 38 studies of predominantly European ancestry (41,890 cases and 41,607 controls) and nine studies of Asian ancestry (6,269 cases and 6,624 controls). The BRCA2 c.9104A>C, p.Tyr3035Ser (OR = 2.52; P = 0.04), and BRCA1 c.5096G>A, p.Arg1699Gln (OR = 4.29; P = 0.009) variant were associated with moderately increased risks of breast cancer among Europeans, whereas BRCA2 c.7522G>A, p.Gly2508Ser (OR = 2.68; P = 0.004), and c.8187G>T, p.Lys2729Asn (OR = 1.4; P = 0.004) were associated with moderate and low risks of breast cancer among Asians. Functional characterization of the BRCA2 variants using four quantitative assays showed reduced BRCA2 activity for p.Tyr3035Ser compared with wild-type. Overall, our results show how BRCA2 missense variants that influence protein function can confer clinically relevant, moderately increased risks of breast cancer, with potential implications for risk management guidelines in women with these specific variants. (C) 2017 AACR.

Original languageEnglish
Pages (from-to)2789-2799
Number of pages11
JournalCancer Research
Volume77
Issue number11
Publication statusPublished - 1-Jun-2017

    Keywords

  • UNKNOWN CLINICAL-SIGNIFICANCE, CELL-BASED ASSAY, UNCERTAIN SIGNIFICANCE, OVARIAN-CANCER, UNCLASSIFIED VARIANTS, SEQUENCE VARIANTS, DNA-BINDING, FUNCTIONAL-EVALUATION, GENES, CLASSIFICATION

ID: 47499730